PORTON BIOPHARMA & DESIGN

View On IC.GC.CA

REGISTERED

on 19 Feb 2020

Last Applicant/ Owned by

PORTON BIOPHARMA LIMITED

Manor Farm Road, Porton, SalisburyWiltshire SP4 0JG

Serial Number

1744853 filed on 4^th Sept 2015

Registration Number

TMA1073048 registered on 19^th Feb 2020

Registration expiry Date

19^th Feb 2030

Correspondent Address

LAVERY, DE BILLY, LLP

1 Place Ville Marie, Suite 4000Montréal

QUÉBEC

H3B4M4

PORTON BIOPHARMA & DESIGN

Trademark usage description

pharmaceutical and veterinary preparations namely biologics and biopharmaceuticals in the form of vaccines, blood products namely, blood for medical p Read More

Vienna Information

14 . 3 . 21

Springs -- Notes: (a) Includes all springs, of whatever kind or for whatever purpose. -- (b) Does not include door closers (15.1.25).Ressorts -- Notes: (a) Comprend tous les ressorts, quel que soit leur genre ou leur destination. -- (b) Non compris les ferme-porte (15.1.25).

26 . 1 . 1

CirclesCercles

26 . 1 . 4

Two circles, two ellipses, one inside the otherDeux cercles, deux ellipses, l'un dans l'autre

26 . 1 . 24

Circles or ellipses with dark surfaces or parts of surfacesCercles ou ellipses avec surface ou partie de la surface foncée

Classification Information

Class [005]
Pharmaceutical and veterinary preparations namely biologics and biopharmaceuticals in the form of vaccines, blood products namely, blood for medical purposes, blood plasma, blood substitutes, reagent blood cells, blood proteins, immunoglobulins and immunomodulatory compounds, therapeutic proteins, gene therapies, and living tissue used to protect against infectious disease namely disorders caused by bacteria, viruses, fungi and parasites and treat cancers, rheumatoid diseases and disorders, skin diseases and disorders namely myeloma and non-melanoma skin cancer and skin infections caused by microbial pathogens, immune system diseases namely autoimmune diseases, immunologic deficiency syndromes, anemia and diseases of the blood namely myelomas, leukaemia and those affecting plasma and white blood cells namely thalassemia, lymphoma, myelodysplastic syndrome, neutropenia, leukocytosis, leukopenia, gastrointestinal diseases and disorders, and neurological diseases namely Alzheimer's, Huntington's Disease, cerebral palsy, Parkinson's disease, multiple sclerosis, cerebrovascular accident (stroke), encephalitis, epilepsy, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, neurodegeneration, amyotrophic lateral sclerosis, peripheral neuropathy, encephalopathy, myasthenia gravis, myopathy, dystonia, spinocerebellar ataxia, demyelinating disease, dysarthria, Guillain-Barré syndrome, chorea, Friedreich's ataxia, polyneuropathy, progressive supranuclear palsy, neuromyelitis optica, motor neurone disease and encephalomyelitis; sanitary preparations for medical purposes namely all purpose disinfectants; materials for dressings namely medical plasters; material for stopping teeth, dental wax; preparations for destroying vermin; fungicides, herbicides; injectable pharmaceutical compositions and preparations comprising compounds having asparaginase activity for the treatment of cancer; pharmaceutical compositions for the treatment of neoplastic conditions namely leukaemia and lymphoma in the blood forming organs

Classification kind code

Mark Details

Serial Number

1744853

Mark Type

Trademark

Legal History

Action Taken	Status
Submitted for opposition 15 on 31^st Oct 2018	Correspondence Created
Submitted for opposition 68 on 5^th Sept 2018	Rep for Service Name Changed
Submitted for opposition 67 on 5^th Sept 2018	Agent Name Changed
Submitted for opposition 15 on 6^th Nov 2017	Correspondence Created
Submitted for opposition 15 on 9^th Dec 2016	Correspondence Created
Submitted for opposition 22 on 1^st Mar 2016	Search Recorded
Submitted for opposition 20 on 1^st Mar 2016	Examiner's First Report
Submitted for opposition 31 on 9^th Sept 2015	Formalized
Submitted for opposition 1 on 8^th Sept 2015	Created
Submitted for opposition 30 on 4^th Sept 2015	Filed